Modulating growth factor signaling through precise and novel treatments
Our goal is to preserve and restore organ function in a range of acute and chronic conditions associated with tissue injury, inflammation, fibrosis and degeneration.
About Us
Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
News & Events
PR
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M
July 2022
PR
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
January 2022
“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
-
Tim Knotnerus, Chief Executive Officer
